Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Atherosclerosis Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Atherosclerosis Overview | 18 | 1 |
| Pipeline Products for Atherosclerosis Comparative Analysis | 19 | 1 |
| Atherosclerosis Therapeutics under Development by Companies | 20 | 3 |
| Atherosclerosis Therapeutics under Investigation by Universities/Institutes | 23 | 2 |
| Atherosclerosis Pipeline Products Glance | 25 | 3 |
| Late Stage Products | 25 | 1 |
| Clinical Stage Products | 26 | 1 |
| Early Stage Products | 27 | 1 |
| Atherosclerosis Products under Development by Companies | 28 | 4 |
| Atherosclerosis Products under Investigation by Universities/Institutes | 32 | 2 |
| Atherosclerosis Companies Involved in Therapeutics Development | 34 | 39 |
| Ache Laboratorios Farmaceuticos S/A | 34 | 1 |
| advanceCor GmbH | 35 | 1 |
| AFFiRiS AG | 36 | 1 |
| Akcea Therapeutics Inc | 37 | 1 |
| Amgen Inc. | 38 | 1 |
| Arisaph Pharmaceuticals, Inc. | 39 | 1 |
| ARMO Biosciences, Inc. | 40 | 1 |
| Artery Therapeutics, Inc. | 41 | 1 |
| Athera Biotechnologies AB | 42 | 1 |
| Cardax, Inc. | 43 | 1 |
| Cerenis Therapeutics Holding SA | 44 | 1 |
| ChemoCentryx, Inc. | 45 | 1 |
| CohBar, Inc. | 46 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 47 | 1 |
| Daiichi Sankyo Company, Limited | 48 | 1 |
| DoNatur GmbH | 49 | 1 |
| Dybly AG | 50 | 1 |
| GenKyoTex S.A. | 51 | 1 |
| HitGen LTD | 52 | 1 |
| Jenrin Discovery, Inc. | 53 | 1 |
| Kang Stem Biotech Co., Ltd. | 54 | 1 |
| KineMed, Inc. | 55 | 1 |
| Kowa Company, Ltd. | 56 | 1 |
| La Jolla Pharmaceutical Company | 57 | 1 |
| Lead Discovery Center GmbH | 58 | 1 |
| LipimetiX Development Inc | 59 | 1 |
| Merck &Co., Inc. | 60 | 1 |
| Omeros Corporation | 61 | 1 |
| Otsuka Holdings Co., Ltd. | 62 | 1 |
| Resverlogix Corp. | 63 | 1 |
| The Medicines Company | 64 | 1 |
| Therapix Biosciences Ltd. | 65 | 1 |
| Tolerys SA | 66 | 1 |
| Unity Biotechnology, Inc. | 67 | 1 |
| Vascular Biogenics Ltd. | 68 | 1 |
| Vericel Corporation | 69 | 1 |
| Vicore Pharma AB | 70 | 1 |
| Vitae Pharmaceuticals, Inc. | 71 | 1 |
| XBiotech Inc | 72 | 1 |
| Atherosclerosis Therapeutics Assessment | 73 | 14 |
| Assessment by Monotherapy Products | 73 | 1 |
| Assessment by Combination Products | 74 | 1 |
| Assessment by Target | 75 | 4 |
| Assessment by Mechanism of Action | 79 | 4 |
| Assessment by Route of Administration | 83 | 2 |
| Assessment by Molecule Type | 85 | 2 |
| Drug Profiles | 87 | 133 |
| 2-CCPA Drug Profile | 87 | 1 |
| AEM-28 Drug Profile | 88 | 2 |
| AM-0010 Drug Profile | 90 | 3 |
| anacetrapib Drug Profile | 93 | 2 |
| Annexin A-5 Drug Profile | 95 | 1 |
| apabetalone Drug Profile | 96 | 10 |
| APTA-5278 Drug Profile | 106 | 1 |
| ARI-1778 Drug Profile | 107 | 1 |
| ATH-04 Drug Profile | 108 | 1 |
| ATH-06 Drug Profile | 109 | 1 |
| BSN-272 Drug Profile | 110 | 1 |
| C-21 Drug Profile | 111 | 2 |
| CCX-771 Drug Profile | 113 | 1 |
| CDX-085 Drug Profile | 114 | 2 |
| Cell Therapy for Atherosclerosis Drug Profile | 116 | 1 |
| Cellular Immunotherapy for Atherosclerosis Drug Profile | 117 | 1 |
| CER-209 Drug Profile | 118 | 1 |
| CM-7 Drug Profile | 119 | 1 |
| COR-2 Drug Profile | 120 | 1 |
| D-4F Drug Profile | 121 | 1 |
| DIAS-2 Drug Profile | 122 | 1 |
| Dipep Drug Profile | 123 | 1 |
| Drug for Atherosclerosis Drug Profile | 124 | 1 |
| Drug for Atherosclerosis Drug Profile | 125 | 1 |
| Drugs to Activate TLR3 for Atherosclerosis Drug Profile | 126 | 1 |
| DWJ-210 Drug Profile | 127 | 1 |
| DYB-186 Drug Profile | 128 | 1 |
| ecraprost Drug Profile | 129 | 2 |
| EP-80317 Drug Profile | 131 | 1 |
| Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis Drug Profile | 132 | 1 |
| Gene Therapy to Activate Interleukin 10 for Atherosclerosis Drug Profile | 133 | 1 |
| Gene Therapy to Activate Telomerase for Alzheimer s Disease and Atherosclerosis Drug Profile | 134 | 1 |
| GKT-831 Drug Profile | 135 | 3 |
| GYY-4137 Drug Profile | 138 | 1 |
| Humanin Drug Profile | 139 | 1 |
| IMMH-007 Drug Profile | 140 | 1 |
| INV-88 Drug Profile | 141 | 1 |
| IONIS-APOARX Drug Profile | 142 | 3 |
| ITP-01 Drug Profile | 145 | 1 |
| ixmyelocel-T Drug Profile | 146 | 6 |
| JD-2000 Series Drug Profile | 152 | 1 |
| JD-5000 Series Drug Profile | 153 | 1 |
| JD-6000 Series Drug Profile | 154 | 1 |
| K-312 Drug Profile | 155 | 1 |
| KM-011 Drug Profile | 156 | 1 |
| leucine + niacin Drug Profile | 157 | 1 |
| liothyronine Drug Profile | 158 | 1 |
| LJPC-6417 Drug Profile | 159 | 1 |
| LPC-01 Drug Profile | 160 | 1 |
| MCC-950 Drug Profile | 161 | 1 |
| MCS-18 Drug Profile | 162 | 2 |
| MDCO-216 Drug Profile | 164 | 3 |
| melittin Drug Profile | 167 | 1 |
| Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis Drug Profile | 168 | 1 |
| Oligonucleotide for Hyperlipidemia and Atherosclerosis Drug Profile | 169 | 1 |
| P-16 Drug Profile | 170 | 1 |
| PC-mAb Drug Profile | 171 | 2 |
| PDI-41 Drug Profile | 173 | 1 |
| pemafibrate Drug Profile | 174 | 2 |
| Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis Drug Profile | 176 | 1 |
| Recombinant Protein for Atherosclerosis and Hepatic Steatosis Drug Profile | 177 | 1 |
| Recombinant Protein for Cardiovascular Diseases Drug Profile | 178 | 1 |
| Recombinant Proteins for Atherosclerosis, Ischemic Stroke and Thrombosis Drug Profile | 179 | 1 |
| Small Molecule for Atherosclerosis Drug Profile | 180 | 1 |
| Small Molecule for Atherosclerosis and Hyperlipidemia Drug Profile | 181 | 1 |
| Small Molecule for Atherosclerosis and Insulin Resistance Drug Profile | 182 | 1 |
| Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology Drug Profile | 183 | 1 |
| Small Molecule to Agonize Liver X Receptor for Atherosclerosis Drug Profile | 184 | 1 |
| Small Molecule to Agonize LXRB for Atherosclerosis Drug Profile | 185 | 1 |
| Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders Drug Profile | 186 | 1 |
| Small Molecule to Inhibit microRNA-223 for Atherosclerosis Drug Profile | 187 | 1 |
| Small Molecule to Target GPR132 for Cardiovascular Diseases Drug Profile | 188 | 1 |
| Small Molecules for Atherosclerosis Drug Profile | 189 | 1 |
| Small Molecules for Atherosclerosis Drug Profile | 190 | 1 |
| Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity Drug Profile | 191 | 1 |
| Small Molecules to Inhibit Chymase for Atherosclerosis Drug Profile | 192 | 1 |
| Small Molecules to Inhibit Lipase for Atherosclerosis Drug Profile | 193 | 1 |
| Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis Drug Profile | 194 | 1 |
| Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile | 195 | 2 |
| SPX-7233801 Drug Profile | 197 | 1 |
| SR-9009 Drug Profile | 198 | 1 |
| Stem Cell Therapy for Atherosclerosis Drug Profile | 199 | 1 |
| Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans Drug Profile | 200 | 1 |
| SURE-NAC Drug Profile | 201 | 1 |
| Synthetic Peptide to Inhibit F11R for Atherosclerosis Drug Profile | 202 | 2 |
| Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease Drug Profile | 204 | 1 |
| Synthetic Peptides for Oncology, Sepsis and Atherosclerosis Drug Profile | 205 | 1 |
| Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation Drug Profile | 206 | 1 |
| Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration Drug Profile | 207 | 2 |
| TRX-318 Drug Profile | 209 | 2 |
| TT-301 Drug Profile | 211 | 1 |
| Vaccine for Atherosclerosis Drug Profile | 212 | 1 |
| Vaccine for Atherosclerosis Drug Profile | 213 | 1 |
| Vaccine for Atherosclerosis Drug Profile | 214 | 1 |
| Vaccine for Autoimmune Disease, Cardiovascular Disease, Immunology, Infectious Disease and Oncology Drug Profile | 215 | 1 |
| VB-201 Drug Profile | 216 | 3 |
| VTP-4 Drug Profile | 219 | 1 |
| Atherosclerosis Dormant Projects | 220 | 12 |
| Atherosclerosis Discontinued Products | 232 | 3 |
| Atherosclerosis Product Development Milestones | 235 | 16 |
| Featured News &Press Releases | 235 | 1 |
| Aug 30, 2016: The Medicines Company Provides Update on MDCO-216 | 235 | 1 |
| Feb 25, 2016: Cerenis Therapeutics featured prominently at the 25th Conference of the ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER (APASL) | 235 | 1 |
| Jan 25, 2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal | 236 | 1 |
| Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy | 236 | 2 |
| Jul 22, 2015: Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet | 238 | 1 |
| Jun 18, 2015: Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin | 239 | 1 |
| Mar 11, 2015: The Medicines Company Provides new data on MDCO-216 at 2015 American College of Cardiology Scientific Sessions in San Diego | 239 | 1 |
| Jan 07, 2015: Interleukin Announces Collaboration with Isis Pharmaceuticals for Genetic Testing Services | 240 | 1 |
| Nov 14, 2014: The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 at 2014 AHA Annual Scientific Sessions in Chicago | 240 | 1 |
| May 21, 2014: Resverlogix Corporation Release: Leading Life Science Publication SciBX Highlights RVX-208 | 241 | 1 |
| May 19, 2014: Recent Studies Further Demonstrate Astaxanthin s Potential As A Safe And Effective Anti-Inflammatory | 242 | 5 |
| Mar 31, 2014: Cleveland Clinic Presents RVX-208 Data at American College of Cardiology Conference | 247 | 1 |
| Mar 17, 2014: Resverlogix Receives European Patent For RVX-208 | 248 | 1 |
| Jan 15, 2014: Resverlogix Announces Combined RVX-208 findings from SUSTAIN &ASSURE Phase 2b Trials | 249 | 1 |
| Jan 02, 2014: Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist | 249 | 2 |
| Appendix | 251 | 2 |
| Methodology | 251 | 1 |
| Coverage | 251 | 1 |
| Secondary Research | 251 | 1 |
| Primary Research | 251 | 1 |
| Expert Panel Validation | 251 | 1 |
| Contact Us | 251 | 1 |
| Disclaimer | 252 | 1 |